Program

July 29th（Thu）

Session1

Viral latency and pathogenesis

9:15-10:45 JST

Chairs
Paul M Lieberman (Gene Expression & Regulation Program, The Wistar Institute, USA)
Micah Luftig (Department of Molecular Genetics and Microbiology, Duke University, USA)
S1-1
Tyrosine-Dependent EBNA1-DNA Cross-Linking Promotes Replication Termination at oriP and Viral Episome Maintenance
Speaker
Paul M Lieberman (The Wistar Institute)
S1-2
Epstein-Barr Virus Subverts Methionine and Folate Metabolism to Maintain Highly Restricted Latency in Burkitt Tumor Cells
Speaker
Rui Guo (Brigham and Women's Hospital)
S1-3
A DNA tumor virus globally reprograms host 3D genome architecture 3 to achieve immortal growth
Speaker
Chong Wang (Brigham and Women's Hospital)
S1-4
Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas
Speaker
Emmanuela N. Bonglack (Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, 27710)
S1-5
Comparison of cellular and viral gene expression in B cells infected with Type 1 versus type 2 EBV by bulk and single cell RNAseq analyses reveals distinct phenotypes
Speaker
Jillian Bristol (University of Wisconsin - Madison)
S1-6
Novel replisome-associated proteins at cellular replication forks in EBV-transformed B lymphocytes
Speaker
Huanzhou Xu (Division of Infectious Diseases, Dept. of Pediatrics, University of Florida)

Session2

Viral replication and reactivation

10:45-12:00 JST

Chairs
Sankar Swaminathan (Department of Medicine, University of Utah, USA)
Sumita Bhaduri-McIntosh (Division of Infectious Diseases, Depts. of Pediatrics and Molecular Genetics and Microbiology, University of Florida)
S2-1
EBV uses the NLRP3 inflammasome as a security system to sense danger and exit from latency
Speaker
Sumita Bhaduri-McIntosh (Division of Infectious Diseases, Dept. of Pediatrics, University of Florida)
S2-2
Hippo Signaling Effectors YAP and TAZ Induce Epstein-Barr Virus (EBV) Lytic Reactivation Through TEADs in Epithelial Cells
Speaker
Nick Van Sciver (Department of Oncology, School of Medicine and Public Health, University of Wisconsin-Madison)
S2-3
Cellular chromatin reorganization by Epstein-Barr Virus during its lytic phase
Speaker
Quincy Rosemarie (University of Wisconsin - Madison)
S2-4
Potential role of EBV lytic reactivation in enhancing ACE2-dependent SARS-CoV-2 infection.
Speaker
Dinesh Verma
(Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, 84132 USA)
S2-5
Single Cell Assay Approaches for Defining the Roles of MicroRNAs and Gene Expression Changes in the Epstein-Barr Virus Reactivation Process
Speaker
Rodney P Kincaid (Oregon Health & Science University)

Luncheon Seminar1

Sponsored by：Chugai Pharmaceutical Co., Ltd.

LS-1
Pathogenesis and Genomic Changes during leukemic transformation in patients with HTLV-1-associated neuroinflammatory disease

12:00-13:00 JST

Chair
Ayako Arai(Division of Hematology-Oncology, Department of Internal Medicine, St. Marianna University, Japan)
Speaker
Yoshihisa Yamano(Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine)

Session3

Nasopharyngeal and gastric carcinoma

13:00-15:00 JST

Chairs
Teruhito Yasui (Laboratory of Infectious Diseases and Immunity National Institute of Biomedical Innovation, Health and Nutrition, Japan)
Kwok-Wai Lo (Department of Anatomical & Cellular Pathology Chinese, University of Hong Kong, China)
S3-1
Genome sequence analysis clarifies Epstein-Barr virus genome variations enhance clinicopathological features of nasopharyngeal cancer in a non-endemic region, Japan
Speaker
Satoru Kondo (Kanazawa Univ.)
S3-2
Comparison of efficacy of a new antibody marker anti-BNLF2b, EBV-DNA and EBV-IgA antibody against EBV in the diagnosis of nasopharyngeal carcinoma
Speaker
Xia Yu (Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University)
S3-3
Epigenomic rewiring by EBV infection in nasopharyngeal carcinoma
Speaker
Harue Mizokami (Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Japan)
S3-4
Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma
Speaker
Qian Zhong (Sun Yat-sen University Cancer Center)
S3-5
Heterochromatin disruption and chromatin structural rewiring induced by Epstein-Barr virus infection in gastric adenocarcinoma
Speaker
Atsushi Okabe (Department of Molecular Oncology, Graduate School of Medicine, Chiba University)
S3-6
The molecular mechanisms of maintaining cancer stem cells in EBV-associated gastric carcinoma
Speaker
Mariko Yasui (Department of Pathology, Graduate School of Medicine, the University of Tokyo)
S3-7
A novel demethylating agent, MC180295 inhibited EBVaGC cell growth by suppressing DNA repair and cell cycle
Speaker
Soichiro Fukuda (Department of Laboratory Science, Yamaguchi University Graduate School of Medicine)
S3-8
Helicobacter pylori promotes gastric epithelial infection of EBV by inducing EphA2 and NMHC-IIA.
Speaker
Hisashi Iizasa (Department of Microbiology, Faculty of Medicine, Shimane University)

Invited Lecture1

IL-1
Epstein-Barr Virus Shaping of the Nasopharyngeal Carcinoma Genomic Landscape

15:00-15:30 JST

Chair
Tomokazu Yoshizaki (Department of Otolaryngology-Head and Neck Surgery, Kanazawa University)
Speaker
Kwok Wai Lo (Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China)

Keynote Lecture1

KL-1
How EBV overcomes cellular barriers and reorganizes cellular organelles for replication and assembly of virions

15:30-16:00 JST

Chair
Asuka Nanbo (National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Japan)
Speaker
Mei-Ru Chen (Graduate Institute and Department of Microbiology, National Taiwan University, Taiwan)

Session4

Chronic Active EBV Infection, nasal NK/T-cell lymphoma, and post-transplant lymphoproliferative disorder

16:00-18:00 JST

Chairs
Hiroshi Kimura (Department of Virology, Nagoya University)
Lorenzo Leoncini (Department of Medical Biotechnology, Section of Pathology, University of Siena, Italy)
S4-1
Plasma level of IL-1β in Chronic Active EBV Infection can be a biomarker of angiopathy
Speaker
Ayaka Ohashi (Department of Frontier Medicine, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa)
S4-2
Clinical investigation of 62 patients with early stage nasal NK/T-cell lymphoma
Speaker
Miki Takahara (Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University)
S4-3
Involvement of Vδ1+ epithelial type of γδT cells expressing NK-cell antigens in the systemic form of hydroa vacciniforme-like lymphoproliferative disorders
Speaker
Keiji Iwatsuki (Okayama University Graduate School of Medicine)
S4-4
IFN-γ, which is Produced by EBV-Positive Neoplastic NK-Cells Induces Macrophage Differentiation and Upregulates Blood Coagulation of which Both Causing HLH.
Speaker
Mayumi Yoshimori (Department of Hematological therapeutics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU))
S4-5
Mucosal-associated invariant T cells are activated in an interleukin-18-dependent manner in Epstein-Barr virus associated T/natural killer cell lymphoproliferative diseases.
Speaker
Yuriko Ishikawa (National Center for Child Health and Development)
S4-6
High throughput drug screening in ENKTL and CAEBV cells identifies synergistic combinations that enhance efficacy of BCL-XL-specific BH3 mimetics.
Speaker
Nenad Sejic (The Walter and Eliza Hall Institute for Medical Research, Parkville, VIC, Australia)
S4-7
Prognostic value of the soluble ZEBRA (Zta) protein in transplant patients with PTLD and Graft versus Host Disease (GVHD)
Speaker
Emmanuel Drouet (Universite Grenoble Alpes, Institut de Biologie Structurale (F))
S4-8
Characterising Epstein Barr virus-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells.
Speaker
Claire Shannon-Lowe (The University of Birmingham)

Henle Lecture

HL
A Journey Through EBV – Henle Lecture 2021

18:00-19:00 JST

Chair
Yasuaki Harabuchi (Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Japan)
Speaker
Paul Farrell (Imperial College London, UK)

July 30 (Fri)

Morning Seminar Sponsored

Sponsored by：Abbott Japan LLC.

MS
The New Discoveries on Chronic Active EBV Infection by the Japanese Researchers ～from their 15 Years of Study～

8:00-9:00 JST

Chair
Hiroshi Kimura(Department of Virology, Nagoya University, Japan)
Speaker
Ayako Arai(Hematology & Oncology, Department of Internal Medicine St. Marianna University)

Session5

Virus-Host interaction and immunity

9:00-10:30 JST

Chairs
Rosemary Rochford (Department of Immunology and Microbiology, University of Colorad.)
Eric Christian Johannsen (Division of Infectious Diseases, Department of Oncology/McArdle Laboratory, University of Wisconsin-Madison, USA)
S5-1
EBV-driven single-cell transcriptional heterogeneity and differential fates in lymphoblastoid cell lines
Speaker
Elliott SoRelle (Department of Molecular Genetics and Microbiology, Duke University)
S5-2
Increased CD4+CD8+ T cells in Multiple Sclerosis (MS) correlate with altered EBV-specific responses and disease outcome.
Speaker
Anna Gil (University of Massachusetts Medical School)
S5-3
The Epstein-Barr virus oncogene EBNA1 suppresses natural killer cell responses early after infection
Speaker
Adityarup Chakravorty (University of Wisconsin-Madison)
S5-4
BGLF2 Interferes with Cellular miRNA Function by Binding RISC
Speaker
Ashley Campbell (Department of Molecular Genetics, University of Toronto)
S5-5
An Air-Liquid Interface Culture Model of the Pseudostratified Epithelium is Susceptible to EBV Infection and Reveals Transcriptional Features of Nasopharyngeal Carcinoma
Speaker
Kathy Ho Yen Shair (Cancer Virology Program, Univ. of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.)
S5-6
Epstein Barr virus-immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice
Speaker
Luwen Zhang (University of Nebraska)

Session6

Lymphomagenesis and therapeutics

10:30-12:00 JST

Chairs
Jeffrey Cohen (National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA)
Ben Gewurz (Brigham & Women's Hospital, Harvard Medical School)
S6-1
CYB561A3 is the Key Lysosomal Iron Reductase Required for Burkitt B-cell Growth and Survival
Speaker
Ben Gewurz (Brigham & Women's Hospital, Harvard Medical School, Boston, MA USA)
S6-2
Mapping antigenic sites of vulnerability on the Epstein-Barr virus fusion machinery
Speaker
Wei Bu
(Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda MD, 20892, USA)
S6-3
T-5224, A SELECTIVE INHIBITOR OF C-FOS/ACTIVATOR PROTEIN-1 INHIBITS EPSTEIN-BARR VIRUS
Speaker
Ibukun A. Akinyemi (Child Health Research Institute, Dept. of Pediatrics, Univ. of Florida, Gainesville, FL)
S6-4
High risk of relapsed disease in patients with NK/T cell chronic active Epstein-Barr virus diseaseoutside of Asia
Speaker
Jeff Cohen (National Institutes of Health, Bethesda, MD)
S6-5
Kaposi Sarcoma in whole KSHV genome transgenic mice
Speaker
Sang-Hoon Sin (The University of North Carolina at Chapel Hill)
S6-6
Removal of CD45RA PBMCs Enables the Generation of Epstein-Barr Virus Specific T-cells from Patients with EBV+ Lymphoma
Speaker
Sandhya Sharma
(Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, Houston Methodist, Houston, TX)

Luncheon Seminar2

Novartis Pharma K.K.

MS
Regulation of hematopoiesis by O-GlcNAcylation

12:00-13:00 JST

Chair
Asuka Nanbo(National Research Center for the Control and Prevention of Infectious Diseases, Nagasaki University, Japan)
Speaker
Hideaki Nakajima(Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine)

Session7

Virus infection and immunity

13:00-14:15 JST

Chairs
Mu-sheng Zeng (Sun Yat-Sen University, China)
Takayuki Murata (Department of Virology and Parasitology, Fujita Health University, Japan)
S7-1
RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells
Speaker
Takayuki Murata (Fujita Health University School of Medicine)
S7-2
Epstein-Barr virus reactivation-induced immunoglobulin production: Significance on Graves' disease
Speaker
Keiko Nagata (Division of Pharmacology, Faculty of Medicine, Tottori University)
S7-3
Epstein-Barr virus transcription factor BZLF1 impairs YTHDF2-mediated mRNA decay of KLF4 by transcriptional repression of METTL3
Speaker
Danling Dai (Sun Yat-sen university cancer center)
S7-4
Exosomes containing Epstein-Barr virus tegument proteins are released from the infected cells and support de novo infection to target cells
Speaker
Yoshitaka Sato (Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan)
S7-5
VSV-based Epstein-Barr Virus gB Elicits Potent Immune Responses
Speaker
Xiangwei Kong
(Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology, South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.)

Invited Lecture2

IL-2
Thirty years of Epstein-Barr virus-associated gastric carcinoma

14:30-15:00 JST

Chair
Hironori Yoshiyama (Department of Microbiology, Shimane University, Japan)
Speaker
Masashi Fukayama (Department of Pathology, Graduate School of Medicine, the University of Tokyo)

Keynote Lecture2

KL-2
EBV in T/NK-cell lymphomagenesis

15:00-15:30 JST

Chair
Keiji Iwatsuki (Okayama University Graduate School of Medicine, Japan)
Speaker
Hiroshi Kimura (Department of Virology, Nagoya University Graduate School of Medicine)

Session8

Virus variation and environment

15:30-17:15 JST

Chairs
Michelle J West (School of Life Sciences, University of Sussex, UK)
Teru Kanda (Division of Microbiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University)
S8-1
Phylogenetic analyses of asymptomatically infected EBV strains derived from Japanese tonsillar tissues in comparison with worldwide non-tumor-derived EBV strains
Speaker
Teru Kanda (Tohoku Medical and Pharmaceutical Univ.)
S8-2
Epstein–Barr virus carrying structural variations in hematological and epithelial cell malignancies
Speaker
Yusuke Okuno (Pediatric Cancer Treatment Center, Nagoya University Hospital, Nagoya, Japan)
S8-3
CryoEM structure of the tegumented capsid of Epstein-Barr virus
Speaker
Xiao Zhang (Sun yat-sen university cancer center)
S8-4
Environmental risk factors for Epstein-Barr virus reactivation in the general population of a high-risk area for nasopharyngeal carcinoma
Speaker
Yufeng Chen (Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden)
S8-5
Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection
Speaker
Ezgi Akidil
(Research Unit Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany)
S8-6
Structure-function analysis of natural variants of Epstein-Barr virus EBNA1
Speaker
Vishwanath Kumble Bhat (School of Life Sciences, University of Sussex, Falmer, Brighton, United Kingdom)
S8-7
Epstein Barr Virus capsid proteins BVRF2 and BdRF1 interact with the autophagy pathway
Speaker
Maria Pena Francesch (Viral immunobiology, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland)